AMPC|cas:2254434-33-6|西域试剂

AMPC,99.44%

产品编号：Bellancom-139065| CAS NO：2254434-33-6| 分子式：C₂₅H₁₆FN₃O₃| 分子量：425.41

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-139065	￥1500.00	杭州北京（现货）
Bellancom-139065	￥2500.00	杭州北京（现货）
Bellancom-139065	￥5500.00	杭州北京（现货）
Bellancom-139065	￥8500.00	杭州北京（现货）
Bellancom-139065	￥13500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AMPC

产品介绍

AMPC 是一种有效的 TFF3 抑制剂。在 TFF3 阳性的 CMS4 结直肠癌细胞中，AMPC 可抑制细胞增殖、存活、致瘤性和 CSC 样行为。AMPC 作为一种潜在的抗癌试剂，可以单独或和 5-FU 联合使用，用于癌症研究。

生物活性

AMPC is a potent and effective TFF3 inhibitor. AMPC inhibits cell proliferation, survival, oncogenicity, and CSC-like behaviour in TFF3-positive CMS4 CRC cells. AMPC acts as a potential anti-cancer agent alone or in combination with 5-FU, and can be used for cancer research.

体外研究

AMPC decreases cell proliferation in CMS4 CRC cells, the IC₅₀ values are 2.63 μM, 4.65 μM, and 69.69 μM, respectively in SW620 (high TFF3 expression), Caco-2, SW480 cells (low TFF3 expression), respectively.
AMPC (1-10 μM) significantly reduces the total cellular levels of TFF3 in SW620 and Caco2 cells in a dose dependent manner.
AMPC induces apoptosis in a dose dependent manner by the inhibition of TFF3, it induces a decrease in the S-phase population and increases caspase3/7 activity compared with control cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

AMPC (intraperitoneal injection; 40 mg/kg; once daily) leads to a significant reduction of tumour volume in AMPC-treated mice as compared to vehicle-treated mice from day 11 onward. AMPC results in larger areas of tumour necrosis and increased area of cells with apoptotic features in SW620 tumours. AMPC also significantly reduces tumour and serum TFF3 levels in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SW620 cells are subcutaneously injected into nude mice
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; 40 mg/kg; once daily
Result:	Lead to tumor decreasein vivo. Results in a marked reduction of Ki67 expression in tumor.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SW620 cells are subcutaneously injected into nude mice
Dosage:	40 mg/kg
Administration:	Intraperitoneal injection; 40 mg/kg; once daily
Result:	Lead to tumor decreasein vivo. Results in a marked reduction of Ki67 expression in tumor.

性状

Solid

溶解性数据

In Vitro:

DMSO : 115 mg/mL (270.33 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3507 mL	11.7534 mL	23.5067 mL
5 mM	0.4701 mL	2.3507 mL	4.7013 mL
10 mM	0.2351 mL	1.1753 mL	2.3507 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 6 mg/mL (14.10 mM); Clear solution

此方案可获得 ≥ 6 mg/mL (14.10 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 60.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.88 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.88 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。